PSX Company Profiles
What listed companies do, how they make money, key financials and Shariah status, researched by the PSX Investors Zone team.
5 companies
Pharmaceuticals
Abbott Laboratories (Pakistan) Limited
Abbott Laboratories (Pakistan) Limited (PSX: ABOT) is a Pakistani pharmaceutical and healthcare company incorporated in 1948. Its business includes branded generic medicines, nutritional products, diagnostics, diabetes care, hospital products and consumer healthcare products. Explore its financial performance, dividend history, Shariah-screening status and key business risks before conducting further investment research.
Pharmaceuticals
AGP Limited
AGP Limited (AGP) is a Pakistan Stock Exchange-listed pharmaceutical company involved in importing, marketing, exporting, distributing, wholesaling and manufacturing pharmaceutical products. In 2025, it reported standalone sales of approximately Rs. 20.55 billion, profit after tax of Rs. 2.36 billion and EPS of Rs. 8.43. Its portfolio and subsidiaries support its presence across Pakistan’s healthcare market. Investors should examine earnings growth, product demand, regulatory requirements, distribution costs, debt and the latest Shariah screening before making investment decisions.
Pharmaceuticals
BF Biosciences Limited
BF Biosciences Limited (BFBIO) is a Pakistan Stock Exchange-listed pharmaceutical company engaged in developing, manufacturing, marketing and distributing pharmaceutical products. It is an 80:20 joint venture between Ferozsons Laboratories Limited and Argentina's Bagó Group. In FY2026, the company reported revenue of Rs.9.46 billion and profit after tax of Rs.632.13 million, reflecting strong year-on-year growth. BFBIO was classified as Shariah-compliant in the PSX screening effective May 29, 2026. Investors should review its latest financial reports, expansion spending, regulatory developments and current Shariah status before making investment decisions.
Pharmaceuticals
Citi Pharma Limited
Citi Pharma Limited (CPHL) is a Pakistan Stock Exchange-listed pharmaceutical manufacturer established in 2012 and listed in 2021. Its principal activities include manufacturing and selling pharmaceutical products, medical chemicals and botanical products. The company’s performance depends on product demand, manufacturing costs, regulatory requirements, raw-material availability, pricing and competition. In FY2026, CPHL reported standalone sales of approximately Rs. 14.00 billion, profit after tax of Rs. 782.60 million and EPS of Rs. 3.43. Investors should review its financial performance, debt, cash flows, valuation, dividend history and latest official Shariah-screening status before making investment decisions.
Pharmaceuticals
The Searle Company Limited
The Searle Company Limited (PSX: SEARL) is a Pakistani pharmaceutical company engaged in manufacturing pharmaceutical and consumer products. Incorporated in 1965, it operates in Pakistan's healthcare and medicines market. In FY2026, the company reported sales of approximately Rs. 31.64 billion, profit after tax of Rs. 4.00 billion and earnings per share of Rs. 6.81. Investors researching SEARL should assess its earnings recovery, product portfolio, margins, regulatory environment, cash flow, Shariah screening status and the Risk Warning Alert displayed on its PSX profile. Past financial performance does not guarantee future results. Sources: https://dps.psx.com.pk/company/SEARL | https://searlecompany.com/investor-information/